Skip to main content

Table 2 Baseline lower respiratory tract pathogens (with a total incidence of ≥ 5%) in ASPECT-NP participants with ventilated hospital-acquired bacterial pneumonia (ITT population and mITT population)

From: Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

ITT population (primary efficacy population)*

LRT pathogen, n (%)

C/T

(N = 75)

Meropenem

(N = 84)

Total

(N = 159)

Gram-negative

74 (98.7)

80 (95.2)

154 (96.9)

 Enterobacterales

47 (62.7)

61 (72.6)

108 (67.9)

  ESBL-positive Enterobacterales

27 (36.0)

25 (29.8)

52 (32.7)

  Klebsiella pneumoniae

32 (42.7)

36 (42.9)

68 (42.8)

  Escherichia coli

10 (13.3)

15 (17.9)

25 (15.7)

  Enterobacter cloacae

4 (5.3)

5 (6.0)

9 (5.7)

  Proteus mirabilis

1 (1.3)

7 (8.3)

8 (5.0)

 Pseudomonas aeruginosa

17 (22.7)

17 (20.2)

34 (21.4)

 Acinetobacter baumannii

19 (25.3)

17 (20.2)

36 (22.6)

 Haemophilus influenzae

5 (6.7)

4 (4.8)

9 (5.7)

Streptococci

3 (4.0)

14 (16.7)

17 (10.7)

mITT population (secondary efficacy population)

LRT pathogen, n (%)

C/T

(N = 55)

Meropenem

(N = 71)

Total

(N = 126)

Gram-negative

54 (98.2)

67 (94.4)

121 (96.0)

 Enterobacterales

37 (67.3)

55 (77.5)

92 (73.0)

  ESBL-positive Enterobacterales

17 (30.9)

23 (32.4)

40 (31.7)

  Klebsiella pneumoniae

21 (38.2)

30 (42.3)

51 (40.5)

  Escherichia coli

10 (18.2)

15 (21.1)

25 (19.8)

  Enterobacter cloacae

4 (7.3)

5 (7.0)

9 (7.1)

  Proteus mirabilis

1 (1.8)

6 (8.5)

7 (5.6)

 Pseudomonas aeruginosa

12 (21.8)

15 (21.1)

27 (21.4)

 Acinetobacter baumannii

5 (9.1)

6 (8.5)

11 (8.7)

 Haemophilus influenzae

5 (9.1)

4 (5.6)

9 (7.1)

Streptococci

3 (5.5)

10 (14.1)

13 (10.3)

  1. C/T, ceftolozane/tazobactam. ESBL, extended-spectrum β-lactamase. ITT, intent-to-treat. LRT, lower respiratory tract. mITT, microbiologic intent-to-treat. n, number of study participants with the specific pathogen. N, number of study participants in the specific treatment arm and analysis population with ≥ 1 baseline LRT
  2. *Study participants were eligible for inclusion into the ITT population regardless of whether they had a baseline pathogen, the type of pathogen, and pathogen susceptibility
  3. Study participants were eligible for inclusion into the mITT population only if baseline LRT cultures yielded ≥ 1 gram-negative or streptococcal respiratory pathogen that was susceptible to ≥ 1 study drug
  4. Since causative gram-positive LRT pathogens other than streptococci are frequently not susceptible to either study drug, microbiology data on non-streptococcal gram-positive pathogens were not captured